Combining flow cytometry and assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.
作者信息
Guolo Fabio, Minetto Paola, Clavio Marino, Miglino Maurizio, Galaverna Federica, Raiola Anna Maria, Di Grazia Carmen, Colombo Nicoletta, Pozzi Sarah, Ibatici Adalberto, Bagnasco Samuele, Guardo Daniela, Kunkl Annalisa, Ballerini Filippo, Ghiggi Chiara, Lemoli Roberto M, Gobbi Marco, Bacigalupo Andrea
机构信息
Clinic of Hematology, Department of internal medicine (DIMI), University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy
Clinic of Hematology, Department of internal medicine (DIMI), University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy.
出版信息
Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11.
Abstract
摘要
相似文献
1
Combining flow cytometry and assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.
Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11.
2
Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Biol Blood Marrow Transplant. 2018 Jan;24(1):55-63. doi: 10.1016/j.bbmt.2017.09.001. Epub 2017 Sep 20.
3
Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
Bone Marrow Transplant. 2017 Apr;52(4):539-543. doi: 10.1038/bmt.2016.318. Epub 2017 Jan 9.
4
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Cancer Med. 2016 Feb;5(2):265-74. doi: 10.1002/cam4.593. Epub 2015 Dec 29.
5
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
Haematologica. 2017 Jan;102(1):110-117. doi: 10.3324/haematol.2016.144253. Epub 2016 Aug 18.
6
Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
Leuk Res. 2017 Oct;61:10-17. doi: 10.1016/j.leukres.2017.08.008. Epub 2017 Aug 30.
7
Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.
Leuk Res. 2012 Aug;36(8):998-1003. doi: 10.1016/j.leukres.2012.04.005. Epub 2012 Apr 30.
8
Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Eur J Haematol. 2014 Sep;93(3):239-46. doi: 10.1111/ejh.12336. Epub 2014 Apr 29.
9
[Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
Zhonghua Er Ke Za Zhi. 2013 Mar;51(3):231-4.
10
Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
Biol Blood Marrow Transplant. 2013 Jun;19(6):958-66. doi: 10.1016/j.bbmt.2013.03.013. Epub 2013 Mar 27.
引用本文的文献
1
Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.
Bone Marrow Transplant. 2025 Feb;60(2):128-134. doi: 10.1038/s41409-024-02481-2. Epub 2024 Nov 20.
2
Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study.
Ann Hematol. 2024 Nov;103(11):4671-4685. doi: 10.1007/s00277-024-06017-y. Epub 2024 Oct 4.
3
Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia.
Front Oncol. 2024 Apr 24;14:1340909. doi: 10.3389/fonc.2024.1340909. eCollection 2024.
4
Measurable residual disease (MRD)-testing in haematological and solid cancers.
Leukemia. 2024 Jun;38(6):1202-1212. doi: 10.1038/s41375-024-02252-4. Epub 2024 Apr 18.
5
The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia.
J Clin Med. 2022 Jun 9;11(12):3306. doi: 10.3390/jcm11123306.
6
Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia.
Cancers (Basel). 2021 Oct 29;13(21):5431. doi: 10.3390/cancers13215431.
7
Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease.
Leuk Res Rep. 2021 Jan 8;15:100234. doi: 10.1016/j.lrr.2021.100234. eCollection 2021.
8
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
J Clin Oncol. 2021 Mar 1;39(7):768-778. doi: 10.1200/JCO.20.02308. Epub 2020 Dec 29.
9
Minimal residual disease and stem cell transplantation outcomes.
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):617-625. doi: 10.1182/hematology.2019000006.
10
Strategies for minimal residual disease detection: current perspectives.
Blood Lymphat Cancer. 2019 Feb 12;9:1-8. doi: 10.2147/BLCTT.S172693. eCollection 2019.
本文引用的文献
1
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Exp Hematol. 2017 May;49:25-33. doi: 10.1016/j.exphem.2017.01.005. Epub 2017 Feb 1.
2
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
3
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2016 Jul;22(7):1242-1246. doi: 10.1016/j.bbmt.2016.03.005. Epub 2016 Mar 10.
4
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
J Clin Oncol. 2016 Feb 1;34(4):329-36. doi: 10.1200/JCO.2015.63.3826. Epub 2015 Dec 14.
5
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):222-33. doi: 10.1182/asheducation-2014.1.222. Epub 2014 Nov 18.
6
Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Eur J Haematol. 2014 Sep;93(3):239-46. doi: 10.1111/ejh.12336. Epub 2014 Apr 29.
7
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.
8
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
Leuk Res. 2013 Dec;37(12):1606-11. doi: 10.1016/j.leukres.2013.07.005. Epub 2013 Jul 23.
9
Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression.
Br J Haematol. 2013 Feb;160(4):503-9. doi: 10.1111/bjh.12181. Epub 2013 Jan 7.
10
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Blood. 2012 Oct 4;120(14):2826-35. doi: 10.1182/blood-2012-06-435669. Epub 2012 Aug 8.
Zotero 插件